ESTRO 2025 - Abstract Book

S844

Clinical - Gynaecology

ESTRO 2025

Conclusion: Our findings align with the PORTEC-3 trial, showing improved OS and DFS when optimal treatment timelines are followed. The inverted protocol offers a viable, safe alternative to PORTEC-3, especially in low- and middle-income countries with limited radiotherapy access, as it allows better control of distant disease by administering chemotherapy before radiotherapy.

Keywords: High risk endometrial cancer, Adjuvant CT-RT,

References: 1. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial de Boer, Stephanie MMcCormack, Mary et al. The Lancet Oncology, Volume 19, Issue 3, 295 - 309